Early-switch versus late-switch in patients with diabetic macular edema: a cost-effectiveness study.

Jose Maria Ruiz-MorenoJorge Ruiz-Medrano

Published in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2022)

In DME eyes, who did not adequately respond to anti-VEGF, switching to DEX-i at early stages (after the first 3-monthly injections) was found to be more cost-effective than extending the treatment to 6-monthly injections of anti-VEGF.

Keyphrases

vascular endothelial growth factor
endothelial cells
platelet rich plasma
ultrasound guided
optical coherence tomography
replacement therapy
smoking cessation